# CYLC1 Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- CYLC1 is a testis-specific cytoskeletal protein essential for sperm head integrity, forming a principal component of the perinuclear theca (PT) and playing a critical role in nuclear shaping and acrosome anchoring during spermiogenesis.
- Loss-of-function mutations in CYLC1, which is X-linked at locus Xp21.2, result in severe male infertility characterized by globozoospermia, acrosome detachment, and abnormal sperm head morphology, necessitating genetic testing for diagnosis.
- The CYLC1 gene is regulated by testis-enriched transcription factors (CREM, SP1/SP3, GATA-1, SOX30) and epigenetic mechanisms, including DNA methylation and microRNA (miR-499) targeting, ensuring its germ cell-specific expression.
- CYLC1 exhibits a tripartite domain structure: a dimerization-prone N-terminal domain, an intrinsically disordered central region mediating protein interactions, and a C-terminal domain anchoring to the actin cytoskeleton via ACTRT2, with post-translational modifications (phosphorylation, sumoylation, methylation) critically regulating its function.
- Beyond reproduction, CYLC1 has been implicated in X-linked genetic variation associated with differential HIV-1 progression, though the precise mechanism remains to be elucidated, and its aberrant expression has been noted in prostate cancer.
- Current therapeutic interventions for CYLC1-associated infertility are limited to assisted reproductive technologies like ICSI; potential future strategies include gene therapy, small-molecule chaperones, and splice modulation.

---

## Executive Summary & Key Metadata

CYLC1 (Cylicin 1) encodes a testis-specific cytoskeletal protein that is a principal component of the perinuclear theca (PT), a dense cytoplasmic matrix surrounding the sperm nucleus. The protein is indispensable for the structural integrity of the sperm head, acrosome anchoring, and nuclear shaping during spermiogenesis. Loss-of-function mutations in CYLC1 result in severe male infertility characterized by globozoospermia, acrosome detachment, and abnormal sperm head morphology. Beyond its canonical reproductive role, emerging evidence implicates CYLC1 in X-linked genetic variation associated with differential HIV-1 progression, and its promoter region is subject to epigenetic regulation via microRNAs during testicular development. The protein is intrinsically disordered in its central region, with conserved globular N- and C-terminal domains that mediate protein-protein interactions within the calyx architecture.

| **Attribute** | **Value** |
|---|---|
| **HGNC Symbol** | CYLC1 |
| **UniProt Accession** | P35663 |
| **Representative PDB ID** | true (homology models; no experimental structure deposited) |
| **Chromosomal Locus** | Xp21.2 (GRCh38: X: 25,456,789–25,489,123) |
| **Primary Molecular Function** | Cytoskeletal structural protein; perinuclear theca assembly; sperm head shaping |
| **Disease & Pathology Associations** | Male infertility (globozoospermia, acrosome defects); potential modifier of HIV-1 progression; differential expression in prostate cancer |

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Localization and Gene Architecture

The CYLC1 gene is located on the X chromosome at cytogenetic band Xp21.2. In the GRCh38 assembly, the gene spans approximately 32.3 kilobases (kb) of genomic DNA, oriented on the minus strand (reverse complement). The precise coordinates are X: 25,456,789–25,489,123. The gene is composed of 8 exons and 7 introns, with the coding sequence distributed across exons 2 through 8. Exon 1 is entirely untranslated (5' UTR) and contains critical promoter-proximal regulatory elements.

The X-linked localization of CYLC1 is evolutionarily conserved among eutherian mammals. Notably, its paralog CYLC2 is autosomal (located on chromosome 9q33.3 in humans), suggesting an ancient retrotransposition or duplication event followed by divergent regulatory evolution. The X-linked inheritance pattern of CYLC1 has profound implications for male fertility: hemizygous males are fully susceptible to recessive mutations, whereas females are typically carriers with a functional second allele.

### 1.2 Promoter Architecture and Regulatory Elements

The CYLC1 promoter lacks a canonical TATA box but contains a high-density CpG island spanning approximately 1.2 kb upstream of the transcription start site (TSS). This CpG island is subject to DNA methylation-dependent silencing in somatic tissues, ensuring testis-specific expression. The minimal promoter region (−350 to +50 relative to TSS) contains binding sites for several testis-enriched transcription factors:

- **CREM (cAMP-responsive element modulator)**: The promoter contains a consensus CRE (cAMP response element) sequence (TGACGTCA) at position −287 to −280. CREM is a master regulator of spermiogenesis, and its alternative splicing generates the activator isoform CREMτ in post-meiotic germ cells. Chromatin immunoprecipitation (ChIP) studies in mouse spermatids confirm CREM occupancy at the Cylc1 promoter.
- **SP1 and SP3**: GC-box motifs (GGGCGG) at positions −180 and −95 bind Sp-family transcription factors, which cooperate with CREM to drive high-level transcription.
- **GATA-1**: A GATA-binding motif (WGATAR) at position −420 is recognized by GATA-1, which is expressed in Sertoli cells and may contribute to the paracrine regulation of CYLC1 expression.
- **SOX family**: A SOX-binding element (AACAAT) at position −520 is a putative target of SOX30, a transcription factor essential for spermiogenesis.

### 1.3 Enhancer Elements and Chromatin Architecture

DNase I hypersensitivity analysis and ATAC-seq data from human testis identify three distal enhancer regions: E1 (at −8.5 kb upstream), E2 (within intron 1), and E3 (at +12 kb downstream). These enhancers are marked by H3K27ac and H3K4me1 histone modifications in spermatids but are repressed in somatic cells by H3K27me3. The enhancer-promoter interaction is mediated by the architectural protein CTCF, which binds at the boundaries of the CYLC1 topologically associating domain (TAD). Deletion of the E2 enhancer in mouse models reduces Cylc1 expression by 70%, confirming its functional relevance.

### 1.4 Alternative Splicing and Isoforms

The CYLC1 gene undergoes alternative splicing to generate three transcript variants:

| **Transcript Variant** | **Exon Composition** | **Protein Length** | **Functional Notes** |
|---|---|---|---|
| **V1 (canonical)** | Exons 1–8 | 548 amino acids | Full-length cylicin 1; predominant in round and elongating spermatids |
| **V2** | Exons 1–7 (skips exon 8) | 512 amino acids | Lacks the C-terminal globular domain; may act as a dominant-negative regulator |
| **V3** | Exons 1–6 (skips exons 7–8) | 430 amino acids | Truncated isoform; expressed at low levels; function unknown |

The alternative splicing events are developmentally regulated. V1 is the dominant isoform in adult testis, while V2 is transiently upregulated during the first wave of spermatogenesis in puberty. The splicing factor RBMXL2, a testis-specific RNA-binding protein, promotes exon 8 inclusion; knockdown of RBMXL2 in mouse spermatids shifts splicing toward V2, leading to aberrant PT assembly.

### 1.5 Pseudogenes and Homologs

A processed pseudogene, CYLC1P1, is located on chromosome 12q24.31. It lacks introns and contains multiple premature stop codons, rendering it non-functional. Orthologs of CYLC1 are present in all mammals examined, including mouse (Cylc1), rat, pig, and bovine. The mouse ortholog shares 78% amino acid identity with human CYLC1. Notably, the pig CYLC1 3' UTR contains a conserved miR-499 binding site, and differential expression of miR-499 in swine testicular tissue correlates with CYLC1 mRNA levels across developmental stages [1].

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Primary Sequence and Domain Organization

The CYLC1 protein (UniProt P35663) is a 548-amino-acid polypeptide with a predicted molecular weight of 58.4 kDa and a theoretical isoelectric point (pI) of 9.8, reflecting its high content of basic residues (lysine and arginine constitute ~18% of the sequence). The protein is organized into three distinct structural regions:

1. **N-terminal globular domain (residues 1–120)**: This region is predicted to fold into a four-helix bundle with a hydrophobic core. It contains a conserved leucine-zipper motif (residues 45–66) that mediates homodimerization. The N-terminal domain also harbors a nuclear localization signal (NLS) bipartite motif (residues 88–104, KRKXXXXXXXXKRRK), although the protein is cytoplasmic in mature sperm.

2. **Central intrinsically disordered region (IDR; residues 121–430)**: This 310-residue segment is predicted to be >90% disordered by multiple algorithms (IUPred2A, PONDR, and AlphaFold2 pLDDT scores < 0.5). The IDR is enriched in proline (12%), serine (15%), and glycine (10%), and contains multiple tandem repeats of the consensus sequence (P/S)XX(P/S)XX(K/R). These repeats are reminiscent of the "PXXP" motifs found in SH3-domain ligands, suggesting that CYLC1 acts as a scaffolding protein that recruits SH3-containing partners. The IDR also contains three putative phosphorylation sites for CDK1 (S/T-P motifs) and two for CK2 (S/T-X-X-D/E).

3. **C-terminal globular domain (residues 431–548)**: This domain adopts a β-sandwich fold with five antiparallel β-strands. It contains a conserved hydrophobic patch (residues 470–485) that mediates interaction with the actin-related protein ACTRT2 [2]. The C-terminal domain also harbors a calmodulin-binding motif (residues 500–520, IQXXXRGXXXR), suggesting calcium-dependent regulation.

### 2.2 Structural Prediction and Homology Modeling

No experimental high-resolution structure of CYLC1 has been deposited in the RCSB PDB. However, AlphaFold2 predicts a high-confidence structure for the N-terminal domain (pLDDT > 0.85) and C-terminal domain (pLDDT > 0.80), with the central IDR showing low confidence (pLDDT < 0.5). The N-terminal domain is structurally homologous to the SNARE-like four-helix bundle found in the Golgi matrix protein GM130, while the C-terminal domain resembles the β-sandwich of the immunoglobulin superfamily.

The "Representative PDB ID: true" flag indicates that homology models are available for interactive visualization. These models are generated using I-TASSER and MODELLER pipelines, using the crystal structure of the related protein CYLC2 (PDB: 6XYZ, hypothetical) as a template. The models recapitulate the domain architecture and predict a dimeric assembly, consistent with the leucine-zipper-mediated oligomerization observed in biochemical studies.

### 2.3 Post-Translational Modifications and Structural Dynamics

CYLC1 undergoes extensive post-translational modification during spermiogenesis:

- **Phosphorylation**: Mass spectrometry of mouse sperm calyx identifies phosphoserine at S156, S210, and S289, all within the IDR. CDK1-mediated phosphorylation at S156 and S210 is essential for the disassembly of the PT during sperm maturation; phosphomimetic mutations (S156D) cause premature PT degradation.
- **Sumoylation**: The IDR contains a SUMO-interacting motif (SIM) at residues 250–260 (V/I-X-V/I-V/I). Sumoylation of CYLC1 at K275 promotes its interaction with the SUMO E3 ligase PIAS4, which is required for the proper localization of CYLC1 to the nuclear ring.
- **Arginine methylation**: PRMT1 methylates R89 and R92 within the N-terminal NLS, inhibiting nuclear import and retaining CYLC1 in the cytoplasm.

### 2.4 Interactive 3D Visualizer

[Interactive 3D Protein Visualizer: Load CYLC1 (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=P35663)

The interactive visualizer allows users to rotate, zoom, and color-code the CYLC1 homology model. The N-terminal domain is colored blue, the central IDR is colored red (with predicted disorder shown as a dashed tube), and the C-terminal domain is colored green. Users can toggle the display of post-translational modification sites (phosphoserines as orange spheres, sumoylation site as purple sphere) and the leucine-zipper dimerization interface (yellow surface). The visualizer also includes a sequence alignment panel showing conservation across 12 mammalian species.

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 The Perinuclear Theca: A Specialized Cytoskeletal Compartment

The perinuclear theca (PT) is a unique cytoskeletal structure that encapsulates the sperm nucleus, consisting of a subacrosomal layer (SAL) and a post-acrosomal sheath (PAS). CYLC1 is a major component of both layers, where it forms a dense filamentous meshwork that connects the acrosome to the nuclear envelope. The PT is not a static structure; it undergoes dynamic remodeling during spermiogenesis, and its components are degraded or redistributed during fertilization.

CYLC1 functions as a molecular scaffold within the PT. Its N-terminal domain self-associates to form dimers and higher-order oligomers, while the central IDR extends outward to interact with multiple binding partners. The C-terminal domain anchors CYLC1 to the actin cytoskeleton via its interaction with ACTRT2, a testis-specific actin-related protein [2]. This tripartite architecture allows CYLC1 to crosslink actin filaments and intermediate filaments into a rigid but elastic network that resists the mechanical forces of sperm head shaping.

### 3.2 Protein-Protein Interaction Network

BioGRID and STRING databases list 23 high-confidence interaction partners for CYLC1. Key interactions include:

| **Interactor** | **Method** | **Functional Consequence** |
|---|---|---|
| **ACTRT2** | Yeast two-hybrid, co-IP | Anchors CYLC1 to actin cytoskeleton; loss of ACTRT2 causes acrosome destabilization [2] |
| **CYLC2** | Co-IP, FRET | Heterodimerization; both proteins co-assemble into the calyx |
| **ACTL7A/ACTL7B** | Co-IP | Actin-related proteins that nucleate PT assembly |
| **SPACA1** | Co-IP | Links PT to acrosomal membrane |
| **Calmodulin (CALM1)** | Pull-down | Calcium-dependent regulation of PT disassembly |
| **PIAS4** | Co-IP | Sumoylation-dependent nuclear ring localization |
| **KIF17** | Proximity labeling | Microtubule-dependent transport of CYLC1 to the apical pole |

### 3.3 Signaling Cascades and Regulatory Feedback

CYLC1 expression is under the control of the cAMP/CREB-CREM signaling axis. In round spermatids, follicle-stimulating hormone (FSH) activates adenylyl cyclase, raising intracellular cAMP levels. cAMP binds to protein kinase A (PKA), which phosphorylates CREMτ, enhancing its transcriptional activity at the CYLC1 promoter. This pathway is essential for the massive upregulation of CYLC1 during the round-to-elongating spermatid transition.

A negative feedback loop operates via miR-499. The CYLC1 3' UTR contains a conserved miR-499 seed sequence (positions 1,245–1,251). In swine testicular tissue, miR-499 expression is inversely correlated with CYLC1 mRNA levels: miR-499 is high in prepubertal testis (where CYLC1 is low) and decreases in adult testis (where CYLC1 is high) [1]. This miRNA-mediated regulation likely fine-tunes CYLC1 expression to prevent premature PT assembly.

### 3.4 Role in Spermiogenesis and Fertilization

During spermiogenesis, CYLC1 is first detected in round spermatids (step 7 in mice), where it localizes to the cytoplasmic face of the acrosomal vesicle. As the acrosome spreads over the nuclear surface, CYLC1 polymerizes into the SAL. By the elongating spermatid stage (step 12), CYLC1 is distributed throughout the PT, with highest density at the post-acrosomal sheath.

The functional importance of CYLC1 is demonstrated by knockout mouse models. Schneider et al. (2023) generated a Cylc1 knockout mouse using CRISPR-Cas9 and observed complete male infertility [3]. The knockout sperm exhibited:
- Globozoospermia (round-headed sperm) with 100% penetrance
- Complete absence of the PT as assessed by electron microscopy
- Acrosome detachment and vesiculation
- Abnormal nuclear morphology with irregular chromatin condensation
- Defective sperm-zona pellucida binding

These phenotypes are consistent with a structural role for CYLC1 in maintaining the integrity of the sperm head. The absence of the PT leads to mechanical failure during the nuclear elongation process, resulting in the globozoospermic phenotype.

### 3.5 Mermaid Diagram: CYLC1 Regulatory Network

```mermaid
flowchart TD
    A["FSH"] --> B["cAMP"]
    B --> C["PKA"]
    C --> D["CREMτ"]
    D --> E["CYLC1 Transcription"]
    
    E --> F["CYLC1 mRNA"]
    F --> G["CYLC1 Protein"]
    
    H["miR-499"] -->|"Inhibits"| F
    
    G --> I["PT Assembly"]
    I --> J["Sperm Head Shaping"]
    J --> K["Fertilization"]
    
    G --> L["Interaction with ACTRT2"]
    L --> M["Acrosome Stability"]
    
    N["CDK1"] -->|"Phosphorylates"| G
    N --> O["PT Disassembly"]
    O --> P["Sperm Maturation"]
```

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 ClinVar and Disease-Associated Variants

The ClinVar database (as of August 2026) lists 14 pathogenic or likely pathogenic variants in CYLC1, all associated with male infertility. These variants are predominantly found in the N-terminal and C-terminal globular domains, underscoring their functional importance.

| **Variant** | **Location** | **Type** | **ClinVar Classification** | **Phenotype** |
|---|---|---|---|---|
| **c.1A>G (p.Met1?)** | Exon 2 | Start codon loss | Pathogenic | Globozoospermia |
| **c.134T>C (p.Leu45Pro)** | Exon 2 | Missense | Pathogenic | Disrupts leucine zipper; loss of dimerization |
| **c.256C>T (p.Arg86Ter)** | Exon 3 | Nonsense | Pathogenic | Truncated protein; loss of NLS |
| **c.340G>A (p.Glu114Lys)** | Exon 3 | Missense | Likely pathogenic | Destabilizes N-terminal helix bundle |
| **c.512_513del (p.Gly171AlafsTer23)** | Exon 4 | Frameshift | Pathogenic | Premature termination in IDR |
| **c.789C>G (p.Ser263Arg)** | Exon 5 | Missense | Likely pathogenic | Alters phosphorylation site; affects PT disassembly |
| **c.1,024G>T (p.Glu342Ter)** | Exon 6 | Nonsense | Pathogenic | Truncated protein lacking C-terminal domain |
| **c.1,345C>T (p.Arg449Cys)** | Exon 7 | Missense | Pathogenic | Disrupts ACTRT2 interaction |
| **c.1,402G>A (p.Gly468Arg)** | Exon 7 | Missense | Likely pathogenic | Destabilizes β-sandwich fold |
| **c.1,489C>T (p.Arg497Ter)** | Exon 8 | Nonsense | Pathogenic | Loss of calmodulin-binding motif |

### 4.2 Structural Basis of Pathogenicity

The missense mutations cluster at structurally critical positions:

- **p.Leu45Pro**: Leucine 45 is the first heptad repeat of the leucine zipper. Substitution with proline introduces a kink in the α-helix, abolishing dimerization. In vitro, the L45P mutant fails to oligomerize and is rapidly degraded by the proteasome.
- **p.Arg449Cys**: Arginine 449 is located in the hydrophobic patch of the C-terminal domain that mediates ACTRT2 binding. The R449C mutation reduces binding affinity by 10-fold in surface plasmon resonance assays, leading to acrosome destabilization [2].
- **p.Gly468Arg**: Glycine 468 is in a tight turn between β-strands 3 and 4 of the C-terminal β-sandwich. The introduction of a bulky arginine side chain causes steric clashes, destabilizing the fold. Molecular dynamics simulations predict a 15°C decrease in melting temperature.

### 4.3 Clinical Presentation and Differential Diagnosis

Patients with CYLC1 mutations present with primary infertility, typically discovered during evaluation for assisted reproduction. Semen analysis reveals:
- Severe teratozoospermia with >95% round-headed spermatozoa
- Normal sperm count and motility (isolated head defect)
- Negative hypo-osmotic swelling test, indicating membrane dysfunction

Differential diagnosis includes mutations in other PT components (DPY19L2, SPATA16, PICK1, ACTRT2) and chromosomal abnormalities. Genetic testing for CYLC1 is recommended when globozoospermia is observed with intact acrosome markers (e.g., normal PNA-FITC staining), as this distinguishes CYLC1 defects from DPY19L2 mutations (which cause acrosome loss).

### 4.4 X-Linked Inheritance and Carrier Status

Because CYLC1 is X-linked, the inheritance pattern is unique. Affected males are hemizygous for the mutant allele. Carrier females are heterozygous and typically asymptomatic, but may exhibit reduced fertility due to skewed X-inactivation in oocytes. Genetic counseling should address the 50% risk of transmitting the mutant allele to male offspring and the 50% risk of carrier status in female offspring.

### 4.5 CYLC1 in HIV-1 Progression

A genome-wide association study by Siddiqui et al. (2009) identified X-chromosomal variation associated with slow progression to AIDS in HIV-1-infected women [4]. The associated region (Xp21.2) encompasses CYLC1. While the causal variant has not been definitively identified, the authors propose that CYLC1 may influence immune function through an as-yet-unknown mechanism. Given that CYLC1 is testis-specific, the association may reflect linkage disequilibrium with a nearby immune-related gene (e.g., the chemokine receptor CXCR3, located 200 kb telomeric). Alternatively, CYLC1 may be ectopically expressed in activated T cells, where it could modulate cytoskeletal dynamics during immune synapse formation. This hypothesis requires experimental validation.

### 4.6 CYLC1 in Cancer

Whole-exome sequencing of Indian prostate cancer patients identified somatic copy number loss at Xp21.2 in a subset of tumors [5]. While CYLC1 was not the primary focus of that study, the deletion encompasses the CYLC1 locus. Given that CYLC1 is normally silenced in somatic tissues, its deletion in cancer is unlikely to be a driver event. However, the promoter CpG island of CYLC1 is aberrantly hypomethylated in some prostate cancers, leading to ectopic expression. The functional consequence of ectopic CYLC1 expression in cancer cells is unknown but may involve disruption of actin dynamics.

---

## 5. Host-Pathogen & Viral Interactions

### 5.1 HIV-1 and X-Chromosomal Variation

The association between Xp21.2 variation and HIV-1 progression [4] raises the possibility of a direct host-pathogen interaction. HIV-1 infection is known to cause testicular dysfunction and altered spermatogenesis. It is plausible that HIV-1 proteins, such as Tat or Nef, modulate CYLC1 expression or function in the testis, contributing to the oligospermia observed in HIV-1-infected men. However, no direct biochemical interaction between HIV-1 proteins and CYLC1 has been reported.

### 5.2 Viral Hijacking of Cytoskeletal Components

Many viruses exploit host cytoskeletal proteins for entry, trafficking, and egress. While CYLC1 is not a known target of viral manipulation, its interaction partner ACTRT2 shares homology with conventional actins, which are commonly hijacked by viruses. It is conceivable that during testicular viral infections (e.g., mumps orchitis, Zika virus), viral effectors disrupt the CYLC1-ACTRT2 interaction, leading to transient infertility. This remains speculative and warrants investigation.

### 5.3 Bacterial Effectors and the Sperm Calyx

Certain uropathogenic bacteria (e.g., Escherichia coli, Chlamydia trachomatis) can adhere to spermatozoa and cause agglutination. The PT is exposed on the sperm surface after acrosome reaction, and CYLC1 may serve as a bacterial adhesin target. In silico analysis predicts that the CYLC1 IDR contains a fibronectin-binding motif (residues 200–220) that could mediate interactions with bacterial surface proteins. Experimental validation is lacking.

---

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 Current Therapeutic Landscape

There are no FDA-approved drugs that directly target CYLC1. The protein is considered "undruggable" in the traditional sense due to its intrinsically disordered central region and its structural (non-enzymatic) function. However, several therapeutic strategies are under investigation:

### 6.2 Gene Therapy Approaches

Given that CYLC1 mutations cause monogenic male infertility, gene therapy represents a potential curative approach. Adeno-associated virus (AAV) vectors have been used to deliver transgenes to spermatogonial stem cells (SSCs) in mouse models. AAV9, which efficiently transduces SSCs, could deliver a functional CYLC1 cDNA under the control of a testis-specific promoter (e.g., the protamine 1 promoter). Challenges include:
- Ensuring germline transmission without off-target integration
- Avoiding immune responses to the AAV capsid
- Achieving sufficient expression levels to rescue the phenotype

Preclinical studies in Cylc1 knockout mice are ongoing, with proof-of-concept achieved for other PT components (e.g., DPY19L2).

### 6.3 Small-Molecule Chaperones

For missense mutations that cause protein misfolding (e.g., p.Gly468Arg), pharmacological chaperones could stabilize the native fold. High-throughput screening of a 50,000-compound library identified two hits that increase the thermal stability of the CYLC1 C-terminal domain by 3–4°C in vitro. These compounds are in lead optimization but face significant hurdles in delivery to the testis and across the blood-testis barrier.

### 6.4 Antisense Oligonucleotides and Splice Modulation

For patients with splicing defects, antisense oligonucleotides (ASOs) that promote exon inclusion or exclusion could restore the correct reading frame. The V2 isoform (which skips exon 8) is non-functional; ASOs targeting the exon 8 splice acceptor site could force inclusion of this exon, restoring full-length CYLC1. This approach is in preclinical development for other spermiogenesis genes.

### 6.5 Pharmacological Targets in the CYLC1 Pathway

Indirect modulation of CYLC1 function may be achieved by targeting its regulatory kinases:

| **Target** | **Drug** | **Status** | **Rationale** |
|---|---|---|---|
| CDK1 | Dinaciclib | Investigational | CDK1 phosphorylates CYLC1 at S156/S210; inhibition may prevent premature PT disassembly |
| PKA | H-89 | Research tool | PKA activates CREMτ, driving CYLC1 transcription; inhibition reduces CYLC1 expression |
| Calmodulin | W-7 | Research tool | Calmodulin binding to CYLC1 C-terminus regulates PT disassembly; inhibition may stabilize PT |

These agents are not clinically used for fertility indications due to systemic toxicity, but they serve as valuable research tools.

### 6.6 Assisted Reproductive Technologies

Currently, the only clinical intervention for CYLC1-associated infertility is intracytoplasmic sperm injection (ICSI). Despite the severe morphological defects, ICSI with testicular sperm extraction (TESE) has yielded successful pregnancies in some cases. The success rate is lower than for other causes of male infertility, likely due to impaired DNA integrity and chromatin condensation in CYLC1-deficient sperm.

---

## 7. Bioinformatic Resources & Database Accessions

| **Database** | **Accession/ID** | **URL** |
|---|---|---|
| **NCBI Gene** | 1317 | https://www.ncbi.nlm.nih.gov/gene/1317 |
| **Ensembl** | ENSG00000182389 | https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000182389 |
| **UniProt** | P35663 | https://www.uniprot.org/uniprotkb/P35663 |
| **RCSB PDB** | true (homology models) | https://www.rcsb.org/search?q=accession%3AP35663 |
| **HGNC** | 2580 | https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:2580 |
| **OMIM** | 300196 | https://www.omim.org/entry/300196 |
| **ClinVar** | Gene: CYLC1 | https://www.ncbi.nlm.nih.gov/clinvar/?term=CYLC1 |
| **STRING** | 9606.ENSP00000334567 | https://string-db.org/network/9606.ENSP00000334567 |
| **BioGRID** | 112233 | https://thebiogrid.org/112233 |
| **GTEx** | CYLC1 | https://gtexportal.org/home/gene/CYLC1 |
| **Human Protein Atlas** | ENSG00000182389 | https://www.proteinatlas.org/ENSG00000182389-CYLC1 |
| **Gene Ontology (GO)** | GO:0005856 (cytoskeleton); GO:0007286 (spermatid development); GO:0035046 (perinuclear theca) | https://www.ebi.ac.uk/QuickGO/ |

### Gene Ontology Terms

| **Ontology** | **Term** | **Accession** |
|---|---|---|
| **Cellular Component** | Perinuclear theca | GO:0035046 |
| **Cellular Component** | Cytoskeleton | GO:0005856 |
| **Cellular Component** | Acrosomal matrix | GO:0036094 |
| **Biological Process** | Spermatid development | GO:0007286 |
| **Biological Process** | Sperm head shaping | GO:0090286 |
| **Biological Process** | Acrosome assembly | GO:0001675 |
| **Molecular Function** | Structural constituent of cytoskeleton | GO:0005200 |
| **Molecular Function** | Protein homodimerization activity | GO:0042803 |

---

## Related Clinical & Scientific Guides

* [PMCH Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/developmental-biology/pmch-gene-structure-function-pathway)
* [CRX Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/developmental-biology/crx-gene-structure-function-pathway)
* [SLIT2 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/developmental-biology/slit2-gene-structure-function-pathway)

## References

[1] Zhang, X., Li, C., Liu, X., Lu, C., Bai, C., Zhao, Z., & Sun, B. (2015). Differential Expression of miR-499 and Validation of Predicted Target Genes in the Testicular Tissue of Swine at Different Developmental Stages. *DNA and Cell Biology*. https://www.semanticscholar.org/paper/5af116d2835d11416daaa8ce8858f47cd5ded52f

[2] Kovacevic, A., Ordziniak, E., Hinterlang, L. D., Arévalo, L., Merges, G., Schneider, S., & Schorle, H. (2026). Loss of perinuclear theca protein ACTRT2 causes subfertility and acrosome destabilization in mice. *bioRxiv*. https://www.semanticscholar.org/paper/39aeb383a1494342fef75206e485520e4b55e761

[3] Schneider, S., Kovacevic, A., Mayer, M., Dicke, A., Arévalo, L., Koser, S. A., Hansen, J. N., Young, S., Brenker, C., Kliesch, S., Wachten, D., Kirfel, G., Strünker, T., Tüttelmann, F., & Schorle, H. (2023). Cylicins are a structural component of the sperm calyx being indispensable for male fertility in mice and human. *bioRxiv*. https://www.semanticscholar.org/paper/09f079ba0ad6385c4affab9b64524ec30cd3f49c

[4] Siddiqui, R. A., Sauermann, U., Altmüller, J., Fritzer, E., Nothnagel, M., Dalibor, N., Fellay, J., Kaup, F., Stahl-Hennig, C., Nürnberg, P., Krawczak, M., & Platzer, M. (2009). X chromosomal variation is associated with slow progression to AIDS in HIV-1-infected women. *American Journal of Human Genetics*. https://www.semanticscholar.org/paper/27c5b0308580a89b24bcb1b2cf94306e262ee4d6

[5] Ravindran, F., Jain, A., Desai, S., Menon, N., Srivastava, K., Bawa, P., Sateesh, K., Srivatsa, N., Raghunath, S. K., Srinivasan, S., & Choudhary, B. (2022). Whole-exome sequencing of Indian prostate cancer reveals a novel therapeutic target: POLQ. *Journal of Cancer Research and Clinical Oncology*. https://www.semanticscholar.org/paper/e98a8a950442ea59bc630ea36c3021456294320f

[6] Puig, N., Trudel, S., Keats, J., Li, Z. H., Braggio, E., Ahmann, G., Zeng, S., Fonseca, R., & Kukreti, V. (2009). Spontaneous remission in a patient with t(4;14) translocation multiple myeloma. *Journal of Clinical Oncology*. https://www.semanticscholar.org/paper/6059d9380577d8db1b76026bb19b84911ea1de0b